Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33023
Title: The short-term effects of CGRP monoclonal antibodies on bone turnover: A prospective cohort study.
Austin Authors: Ray, Jason C ;Sztal-Mazer, Shoshana;Baker, Josephine;Matharu, Manjit S;Hutton, Elspeth J
Affiliation: Department of Neurology, Alfred Hospital, Melbourne, Australia.
Department of Endocrinology and Diabetes, Alfred Health, Melbourne, Australia.
Neurology
Headache and Facial Pain Group, University College London, Queen Square Institute of Neurology, London, UK.;The National Hospital for Neurology and Neurosurgery, London, UK.
Department of Neuroscience, Monash University, Melbourne, Australia.
Issue Date: Jun-2023
Publication information: Cephalalgia : an International Journal of Headache 2023-06; 43(6)
Abstract: Calcitonin gene-related peptide monoclonal antibodies (CGRP mAb) are an effective treatment of migraine however may have possible off-target effects. Pre-clinical studies implicate CGRP in several aspects of bone turnover and homeostasis. The clinical effect of CGRP mAb on bone turnover is not known, however. Between June 2021 and July 2022, a multi-centre prospective cohort study was undertaken with eligible patients undergoing paired testing of the validated bone turnover markers procollagen type I N-terminal propeptide (P1NP) and serum C-terminal telopeptide of type I collagen (CTX) prior to and at least three months following administration of a CGRP mAb. A total of 45 patients with a mean age of 41.8 (SD 11.9) were included in the final analysis, all of whom received a ligand-targeting CGRP mAb. Administration of a CGRP mAb was associated with a statistically significant increase in P1NP from 44.5 microg/L to 51.5 microg/L (p = 0.004), but no significant change in CTX. In otherwise homeostatic conditions, short-term administration of a CGRP mAb is associated with increased P1NP, a bone formation marker but not with increased CTX, a bone resorption marker. Further study is required to validate these findings over longer time periods, in a larger cohort, and in pre-existing states of increased calcium stress and bone-turnover.
URI: https://ahro.austin.org.au/austinjspui/handle/1/33023
DOI: 10.1177/03331024231180562
ORCID: 0000-0003-4833-5507
0000-0002-4960-2294
Journal: Cephalalgia : an International Journal of Headache
Start page: 3331024231180562
PubMed URL: 37264889
ISSN: 1468-2982
Type: Journal Article
Subjects: CGRP
CTX
Migraine
P1NP
bone metabolism
bone turnover
Calcitonin Gene-Related Peptide/pharmacology
Peptide Fragments/pharmacology
Appears in Collections:Journal articles

Show full item record

Page view(s)

22
checked on Jun 16, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.